ZEB1 induces N‑cadherin expression in human glioblastoma and may alter patient survival

Gött,Hanna; Nagl,Jasmin; Hagedorn,Frederike; Thomas,Samuel; Schwarm,Frank P.; Uhl,Eberhard; Kolodziej,Malgorzata A.

doi:10.3892/mco.2022.2556

ZEB1 induces N‑cadherin expression in human glioblastoma and may alter patient survival

Authors:
- Hanna Gött
- Jasmin Nagl
- Frederike Hagedorn
- Samuel Thomas
- Frank P. Schwarm
- Eberhard Uhl
- Malgorzata A. Kolodziej
View Affiliations

Affiliations: Department of Neurosurgery, University Hospital Giessen, D‑35392 Giessen, Germany, Department of Pathology, University Hospital Giessen, D‑35392 Giessen, Germany
Published online on: June 8, 2022 https://doi.org/10.3892/mco.2022.2556
Article Number: 123

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study investigated the expression of epithelial‑mesenchymal transition (EMT)‑related factors zinc finger E‑box‑binding homeobox 1 (ZEB1), cadherin‑1 (CDH1), cadherin‑2 (CDH2) and the cell cycle modulating kinase cyclin‑dependent kinase 1 (CDK1) in human glioblastoma (GBM) compared to normal brain tissue, as well as whether the levels of expression were associated with the overall and progression‑free survival of the GBM patients. In 44 GBM and five normal brain tissue specimens, the expression levels of ZEB1, CDH1, CDH2 and CDK1 were evaluated by real‑time PCR and immunostaining, and the results were correlated with clinical data. The expression levels of all investigated genes as detected by immunostaining were significantly higher in the GBM when compared to the normal brain tissues. There was no influence on survival. A linear correlation between ZEB1 and CDH2 and CDK1 expression was observed in GBM. Moreover, ZEB1 was involved in EMT (e.g., signaling in human GBM) and high ZEB1 levels were linked to an aberrant cell cycle processing, marked by CDK1 overexpression.

View Figures

View References

1	Ostrom QT, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C and Barnholtz-Sloan JS: CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014. Neuro Oncol. 19 (Suppl 5):v1–v88. 2017.PubMed/NCBI View Article : Google Scholar
2	Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005.PubMed/NCBI View Article : Google Scholar
3	Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, et al: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10:459–466. 2009.PubMed/NCBI View Article : Google Scholar
4	Delgado-López PD and Corrales-García EM: Survival in glioblastoma: A review on the impact of treatment modalities. Clin Transl Oncol. 18:1062–1071. 2016.PubMed/NCBI View Article : Google Scholar
5	Weller M, van den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan-Moyal E, Henriksson R, Le Rhun E, Balana C, Chinot O, et al: European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol. 18:e315–e329. 2017.PubMed/NCBI View Article : Google Scholar
6	Stupp R and Roila F: ESMO Guidelines Working Group. Malignant glioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 20 (Suppl 4):S126–S128. 2009.PubMed/NCBI View Article : Google Scholar
7	Kalluri R and Weinberg RA: The basics of epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428. 2009.PubMed/NCBI View Article : Google Scholar
8	Pala A, Karpel-Massler G, Rainer C and Eric M: Epithelial to Mesenchymal transition and progression of glioblastoma. In: Clinical Management and Evolving Novel Therapeutic Strategies for Patients with Brain Tumors. Lichtor T (ed). InTech, ISBN 978-953-51-1058-3, 2013.
9	Thiery JP and Sleeman JP: Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 7:131–142. 2006.PubMed/NCBI View Article : Google Scholar
10	Lee JK, Joo KM, Lee J, Yoon Y and Nam DH: Targeting the epithelial to mesenchymal transition in glioblastoma: The emerging role of MET signaling. Onco Targets Ther. 7:1933–1944. 2014.PubMed/NCBI View Article : Google Scholar
11	Iser IC, Lenz G and Wink MR: EMT-like process in glioblastomas and reactive astrocytes. Neurochem Int. 122:139–143. 2019.PubMed/NCBI View Article : Google Scholar
12	Lee JM, Dedhar S, Kalluri R and Thompson EW: The epithelial-mesenchymal transition: New insights in signaling, development, and disease. J Cell Biol. 172:973–981. 2006.PubMed/NCBI View Article : Google Scholar
13	Nieto MA, Huang RY, Jackson RA and Thiery JP: EMT: 2016. Cell. 166:21–45. 2016.PubMed/NCBI View Article : Google Scholar
14	Lamouille S, Xu J and Derynck R: Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 15:178–196. 2014.PubMed/NCBI View Article : Google Scholar
15	Saitoh M: Involvement of partial EMT in cancer progression. J Biochem. 164:257–264. 2018.PubMed/NCBI View Article : Google Scholar
16	Du B and Shim JS: Targeting epithelial-mesenchymal transition (EMT) to overcome drug resistance in cancer. Molecules. 21(965)2016.PubMed/NCBI View Article : Google Scholar
17	Pal A, Barrett TF, Paolini R, Parikh A and Puram SV: Partial EMT in head and neck cancer biology: A spectrum instead of a switch. Oncogene. 40:5049–5065. 2021.PubMed/NCBI View Article : Google Scholar
18	Kahlert UD, Joseph JV and Kruyt FAE: EMT- and MET-related processes in nonepithelial tumors: Importance for disease progression, prognosis, and therapeutic opportunities. Mol Oncol. 11:860–877. 2017.PubMed/NCBI View Article : Google Scholar
19	Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, Waldvogel B, Vannier C, Darling D, zur Hausen A, et al: The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol. 11:1487–1495. 2009.PubMed/NCBI View Article : Google Scholar
20	Edwards LA, Li A, Berel D, Madany M, Kim NH, Liu M, Hymowitz M, Uy B, Jung R, Xu M, et al: ZEB1 regulates glioma stemness through LIF repression. Sci Rep. 7(69)2017.PubMed/NCBI View Article : Google Scholar
21	Madany M, Thomas T and Edwards LA: The curious case of ZEB1. Discoveries (Craiova). 6(e86)2018.PubMed/NCBI View Article : Google Scholar
22	Siebzehnrubl FA, Silver DJ, Tugertimur B, Deleyrolle LP, Siebzehnrubl D, Sarkisian MR, Devers KG, Yachnis AT, Kupper MD, Neal D, et al: The ZEB1 pathway links glioblastoma initiation, invasion and chemoresistance. EMBO Mol Med. 5:1196–1212. 2013.PubMed/NCBI View Article : Google Scholar
23	Schwechheimer K, Zhou L and Birchmeier W: E-cadherin in human brain tumours: Loss of immunoreactivity in malignant meningiomas. Virchows Arch. 432:163–167. 1998.PubMed/NCBI View Article : Google Scholar
24	Howng SL, Wu CH, Cheng TS, Sy WD, Lin PC, Wang C and Hong YR: Differential expression of Wnt genes, beta-catenin and E-cadherin in human brain tumors. Cancer Lett. 183:95–101. 2002.PubMed/NCBI View Article : Google Scholar
25	Camand E, Peglion F, Osmani N, Sanson M and Etienne-Manneville S: N-cadherin expression level modulates integrin-mediated polarity and strongly impacts on the speed and directionality of glial cell migration. J Cell Sci. 125(Pt 4):844–857. 2012.PubMed/NCBI View Article : Google Scholar
26	Utsuki S, Sato Y, Oka H, Tsuchiya B, Suzuki S and Fujii K: Relationship between the expression of E-, N-cadherins and beta-catenin and tumor grade in astrocytomas. J Neurooncol. 57:187–192. 2002.PubMed/NCBI View Article : Google Scholar
27	Asano K, Duntsch CD, Zhou Q, Weimar JD, Bordelon D, Robertson JH and Pourmotabbed T: Correlation of N-cadherin expression in high grade gliomas with tissue invasion. J Neurooncol. 70:3–15. 2004.PubMed/NCBI View Article : Google Scholar
28	Zhang P, Sun Y and Ma L: ZEB1: At the crossroads of epithelial-mesenchymal transition, metastasis and therapy resistance. Cell Cycle. 14:481–487. 2015.PubMed/NCBI View Article : Google Scholar
29	Tian Y, Xie Q, He J, Luo X, Zhou T, Liu Y, Huang Z, Tian Y, Sun D and Yao K: Radioactive (125)I seeds inhibit cell growth and epithelial-mesenchymal transition in human glioblastoma multiforme via a ROS-mediated signaling pathway. BMC Cancer. 15(1)2015.PubMed/NCBI View Article : Google Scholar
30	Vandewalle C, van Roy F and Berx G: The role of the ZEB family of transcription factors in development and disease. Cell Mol Life Sci. 66:773–787. 2009.PubMed/NCBI View Article : Google Scholar
31	Aigner K, Dampier B, Descovich L, Mikula M, Sultan A, Schreiber M, Mikulits W, Brabletz T, Strand D, Obrist P, et al: The transcription factor ZEB1 (deltaEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity. Oncogene. 26:6979–6988. 2007.PubMed/NCBI View Article : Google Scholar
32	Eger A, Aigner K, Sonderegger S, Dampier B, Oehler S, Schreiber M, Berx G, Cano A, Beug H and Foisner R: DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. Oncogene. 24:2375–2385. 2005.PubMed/NCBI View Article : Google Scholar
33	Qi S, Song Y, Peng Y, Wang H, Long H, Yu X, Li Z, Fang L, Wu A, Luo W, et al: ZEB2 mediates multiple pathways regulating cell proliferation, migration, invasion, and apoptosis in glioma. PLoS One. 7(e38842)2012.PubMed/NCBI View Article : Google Scholar
34	Otto T and Sicinski P: Cell cycle proteins as promising targets in cancer therapy. Nat Rev Cancer. 17:93–115. 2017.PubMed/NCBI View Article : Google Scholar
35	Chen H, Huang Q, Zhai DZ, Dong J, Wang AD and Lan Q: CDK1 expression and effects of CDK1 silencing on the malignant phenotype of glioma cells. Zhonghua Zhong Liu Za Zhi. 29:484–488. 2007.PubMed/NCBI(In Chinese).
36	André S, Kojima S, Yamazaki N, Fink C, Kaltner H, Kayser K and Gabius HJ: Galectins-1 and -3 and their ligands in tumor biology. Non-uniform properties in cell-surface presentation and modulation of adhesion to matrix glycoproteins for various tumor cell lines, in biodistribution of free and liposome-bound galectins and in their expression by breast and colorectal carcinomas with/without metastatic propensity. J Cancer Res Clin Oncol. 125:461–474. 1999.PubMed/NCBI View Article : Google Scholar